Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    May 2024
  1. XU M, Li S
    The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
    Cancer Lett. 2024;593:216969.
    PubMed     Abstract available


  2. WANG D, He J, Liu S, Zhang H, et al
    Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia.
    Cancer Lett. 2024 May 17:216970. doi: 10.1016/j.canlet.2024.216970.
    PubMed     Abstract available


  3. TAN Y, Xin L, Wang Q, Xu R, et al
    FLT3-Selective PROTAC: Enhanced Safety and Increased Synergy with Venetoclax in FLT3-ITD Mutated Acute Myeloid Leukemia.
    Cancer Lett. 2024 May 3:216933. doi: 10.1016/j.canlet.2024.216933.
    PubMed     Abstract available


    April 2024
  4. ZHAO Y, Chen W, Yu J, Pei S, et al
    TP53 in MDS and AML: Biological and clinical advances.
    Cancer Lett. 2024;588:216767.
    PubMed     Abstract available


  5. SUN H, Xie Y, Wu X, Hu W, et al
    circRNAs as prognostic markers in pediatric acute myeloid leukemia.
    Cancer Lett. 2024;591:216880.
    PubMed     Abstract available


    March 2024
  6. HE Y, Jiang S, Cui Y, Liang J, et al
    Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis.
    Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797.
    PubMed     Abstract available


    February 2024
  7. CHENG C, Liang S, Yue K, Wu N, et al
    STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vdelta2(+) T cells in acute myeloid leukemia.
    Cancer Lett. 2024 Feb 13:216730. doi: 10.1016/j.canlet.2024.216730.
    PubMed     Abstract available


    January 2024
  8. YANG F, Cui X, Wang H, Zhang D, et al
    Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
    Cancer Lett. 2024 Jan 17:216652. doi: 10.1016/j.canlet.2024.216652.
    PubMed     Abstract available


    December 2023
  9. JUNG YY, Ahn KS, Shen M
    Unveiling autophagy complexity in leukemia: The molecular landscape and possible interactions with apoptosis and ferroptosis.
    Cancer Lett. 2023 Dec 1:216518. doi: 10.1016/j.canlet.2023.216518.
    PubMed     Abstract available


    September 2023
  10. WEN J, Chen Y, Liao C, Ma X, et al
    Engineered mesenchymal stem cell exosomes loaded with miR-34c-5p selectively promote eradication of acute myeloid leukemia stem cells.
    Cancer Lett. 2023 Sep 26:216407. doi: 10.1016/j.canlet.2023.216407.
    PubMed     Abstract available


    June 2023
  11. YE X, Wu Y, Zhang H, Zhou Y, et al
    Rapid generation of CD19 CAR-T cells by minicircle DNA enables anti-tumor activity and prevents fatal CAR-B leukemia.
    Cancer Lett. 2023 Jun 22:216278. doi: 10.1016/j.canlet.2023.216278.
    PubMed     Abstract available


    February 2023
  12. ZHANG R, Liu Q, Zhou S, He H, et al
    Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia.
    Cancer Lett. 2023;558:216103.
    PubMed     Abstract available


    November 2022
  13. HUANG R, Wang X, Zhang X
    Unity brings strength: Combination of CAR-T cell therapy and HSCT.
    Cancer Lett. 2022;549:215721.
    PubMed     Abstract available


  14. ZHOU H, Jiang Y, Huang Y, Zhong M, et al
    Therapeutic inhibition of PPARalpha-HIF1alpha-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia.
    Cancer Lett. 2022 Nov 14:215997. doi: 10.1016/j.canlet.2022.215997.
    PubMed     Abstract available


    July 2022
  15. YE B, Sheng Y, Zhang M, Hu Y, et al
    Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
    Cancer Lett. 2022;538:215691.
    PubMed     Abstract available


    May 2022
  16. ZHENG NS, Zhao XY, Wei D, Miao JL, et al
    CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia.
    Cancer Lett. 2022;542:215762.
    PubMed     Abstract available


    April 2022
  17. YOU R, Wang B, Chen P, Zheng X, et al
    Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells.
    Cancer Lett. 2022;532:215582.
    PubMed     Abstract available


    March 2022
  18. GHIRALDELI L, Anderson R, Pladna K, Pardee TS, et al
    Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML).
    Cancer Lett. 2022;535:215659.
    PubMed     Abstract available


    February 2022
  19. ZHOU Y, Guan L, Li W, Jia R, et al
    DT7 peptide-modified lecithin nanoparticles co-loaded with gamma-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.
    Cancer Lett. 2022 Feb 28:215608. doi: 10.1016/j.canlet.2022.215608.
    PubMed     Abstract available


  20. YAO K, Liu H, Yu S, Zhu H, et al
    Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.
    Cancer Lett. 2022;533:215603.
    PubMed     Abstract available


  21. PATEL SA
    Functional genomic approaches in acute myeloid leukemia: Insights into disease models and the therapeutic potential of reprogramming.
    Cancer Lett. 2022 Feb 3:215579. doi: 10.1016/j.canlet.2022.215579.
    PubMed     Abstract available


    January 2022
  22. GHANI LA, Yusenko MV, Frank D, Moorthy R, et al
    A synthetic covalent ligand of the C/EBPbeta transactivation domain inhibits acute myeloid leukemia cells.
    Cancer Lett. 2022 Jan 22. pii: S0304-3835(22)00040.
    PubMed     Abstract available


    December 2021
  23. KAMACHI K, Ureshino H, Watanabe T, Yoshida N, et al
    Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.
    Cancer Lett. 2021 Dec 4. pii: S0304-3835(21)00607.
    PubMed     Abstract available


    November 2021
  24. YUSENKO MV, Biyanee A, Andersson MK, Radetzki S, et al
    Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
    Cancer Lett. 2021;520:132-142.
    PubMed     Abstract available


    July 2021
  25. LIU Q, Hua M, Zhang C, Wang R, et al
    NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1beta/Th1/IFN-gamma in acute myeloid leukemia.
    Cancer Lett. 2021 Jul 5. pii: S0304-3835(21)00299.
    PubMed     Abstract available


    May 2021
  26. TAVAKOLI SHIRAZI P, Eadie LN, Page EC, Heatley SL, et al
    Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
    Cancer Lett. 2021;512:28-37.
    PubMed     Abstract available


    April 2021
  27. LING Y, Xu N, Zhao K, Han L, et al
    Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia.
    Cancer Lett. 2021;510:59-66.
    PubMed     Abstract available


  28. LEE DH, Kang SH, Choi DS, Ko M, et al
    Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells.
    Cancer Lett. 2021;510:37-47.
    PubMed     Abstract available


  29. LI Y, Li Y, Yin J, Wang C, et al
    A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells.
    Cancer Lett. 2021 Apr 13. pii: S0304-3835(21)00157.
    PubMed     Abstract available


    March 2021
  30. GLENEADIE HJ, Baker AH, Batis N, Bryant J, et al
    The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.
    Cancer Lett. 2021;501:172-186.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.